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Introduction: Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonergic activity in the central nervous 
system. It is characterized by mental status changes (eg, confusion, agitation, lethargy, coma), autonomic instability (eg, hyperthermia, 
tachycardia, diaphoresis, nausea, vomiting, diarrhea, dilated pupils), and neuromuscular hyperactivity (eg, myoclonus, hyperreflexia, 
rigidity, trismus). Serotonin syndrome classically occurs in patients receiving two or more serotonergic drugs, but it can occur with 
monotherapy. We report a case of a 20-year-old man who developed serotonin syndrome resulting from overdose of Escitolapram with 
concomitant use of cocaine. It is a very important area in medicine as serotonin syndrome should be suspected especially in drug abusers 
who are being treated with psychotropic agents for mental illnesses.
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case Report
A 20-year-old male patient was admitted for altered 
mental status and agitation of unknown etiology. His 
past medical history was notable for depression and 
anxiety for which he had recently begun treatment 
with  Escitolapram  (selective  serotonin  re-uptake 
inhibitor),  Qetiapine  (atypical  antipsychotic),  and 
Clonazepam  (benzodiazepine). Approximately  four 
hours  prior  to  admission,  he  had  snorted  multiple 
crushed tablets consisting of Percocet, Escitolapram 
20 mg, Quetiapine 100 mg and Clonazepam because 
of  abdominal  pain  and  worsening  feelings  of 
sadness. He was found at home by his parents. He 
was noted to very agitated and disoriented. He was 
brought immediately to the emergency department. 
His parents couldn’t specify the exact amount of the 
ingested  medications.  It  was  also  reported  that  he 
had been using cocaine for one year for recreational 
purposes.  The  exact  time  of  his  last  recreational 
cocaine use couldn’t be determined as patient was 
non-cooperative.
On admission, the patient was confused, lethar-
gic,  non-communicative,  disoriented  and  agitated 
with Glasgow coma scale score of 10. His physical 
examination  was  significant  for  tachycardia  (133 
beats/minute), elevated body temperature (101.4 °F), 
slow and shallow breathing (11 breaths/minute), dia-
phoresis  and  generalized  anxiousness.  Neurologic 
exam was positive for hyperreflexia, clonus on dorsi-
flexion of the feet, and muscular rigidity. The patient’s 
respiratory rate gradually decreased with acompany-
ing  desaturations  to  80%  necessitating  intubation 
with  mechanical  ventilation.  His  laboratory  results 
revealed no abnormalities including the urine drug 
screen. Computerized tomography of the head and 
lumbar puncture were also unremarkable.
Serotonin  syndrome  was  considered  after  rul-
ing  out  infection  and  cerebrovascular  accidents 
as  potential  etiologies  for  the  patient’s  condition. 
  Escitolapram  was  withheld,  and  the  patient  was 
aggressively  hydrated  with  intravenous  fluids.  He 
received one dose of Lorazepam (2 mg IV push) for 
agitation. Within 24 hours, the patient’s mental status 
had improved and he was able to be extubated. By the 
second hospital day, the patient was declared medi-
cally stable and transferred to the psychiatric ward. 
Percocet  (oxycodone/acetaminophen),  Clonazepam 
and Qetiapine (serotonin, dopamine and adrenergic 
antagonist with negligible anticholinergic properties) 
are known to depress CNS function and may have 
contributed to patient’s mental status but the clinical 
history and physical exam with autonomic instability 
(hyperthermia, tachycardia, diaphoresis) and neuro-
muscular  hyperactivity  (hyperreflexia,  rigidity,  and 
myoclonus)  pointed  more  towards  serotonin  syn-
drome with the main culprits being escitolapram and 
cocaine as they both increase serotonin activity in the 
brain. Cocaine blocks the serotonin uptake and there-
fore  combination  with  escitolapram  is  potentially 
significant.
This case represents a rare incidence of serotonin 
syndrome occurring after an intentional overdose of 
escitolapram. As such, it highlights the importance for 
physicians to maintain a high suspicion for serotonin 
syndrome as a potential diagnosis when encounter-
ing an agitated and confused patient known be on 
serotonin-modifying drugs.
Escitalopram  is  a  selective  serotonin  reuptake 
inhibitor (SSRI), used to treat depression and gen-
eralized  anxiety  disorder.  Therapeutic  doses  range 
from 10 mg/day to 20 mg/day. Our patient’s dose was 
20 mg/day. Common side effects seen with escitol-
apram use are nausea, constipation, diarrhea, dizziness 
and impotence. An adverse effect of escitolapram, as 
with other SSRIs, is the Serotonin syndrome.
1 The 
symptoms  are  variable  and  can  easily  be  missed.1 
No single receptor appears to be responsible for the 
development  of  the  Serotonin  syndrome,  although 
several studies suggest that agonism of serotonin-1A 
(5-HT1A)  and  serotonin-5A  (5-HT2A)  receptors 
contribute  substantially  to  the  condition.2  Cocaine 
prevents serotonin uptake and its combination with 
esciolapram may lead to serotonin syndrome.9
The  diagnosis  of  Serotonin  syndrome  is  made 
clinically.  It  is  characterized  by  mental  status 
changes  (eg,  confusion,  agitation,  lethargy,  coma), 
autonomic  instability  (eg,  hyperthermia,  tachycar-
dia, diaphoresis, nausea, vomiting, diarrhea, dilated 
pupils), and neuromuscular hyperactivity (eg, myo-
clonus,  hyperreflexia,  rigidity,  trismus).1  The  com-
bination of SSRIs with other serotonergic drugs (eg, 
tryptophan,  illicit  drugs  like  cocaine  and  MDMA, 
“ecstasy”)  or  drugs  with  serotonin  properties  (eg, 
lithium, meperidine, triptans) can lead to serotonin 
syndrome.3  Serotonin  syndrome  classically  occurs 
in patients receiving two or more serotonergic drugs, Serotonin syndrome with escitolapram and cocaine
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but it can occur with monotherapy. Selective sero-
tonin reuptake inhibitor (SSRI) monotherapy has an 
incidence of 0.5 to 0.9 cases of SS per 1000 patient-
months.3 Concomitant use of an SSRI with a monoam-
ine oxidase inhibitor (MAOI) poses the greatest risk of 
developing Serotonin syndrome. The Hunter Serotonin 
Toxicity Criteria are used to diagnose serotonin syn-
drome and require the presence of one of the following 
classical features or groups of features: spontaneous 
clonus, inducible clonus with agitation or diaphoresis, 
ocular clonus with agitation or diaphoresis, tremor and 
hyperreflexia,  hypertonia,  temperature  above  100.4 
°F (38 °C), and ocular or inducible clonus.3 There 
are no specific laboratory tests to diagnose Serotonin 
syndrome. Laboratory and other diagnostic tests are 
used to rule out alternative explanations of symptoms. 
Blood 5-HT levels are not useful because it is the local 
concentration at nerve terminals that is responsible for 
the physiologic effects.4,5 A strong clinical suspicion, 
known exposure to serotonergic agents, demonstra-
tion of specific signs and symptoms, and exclusion of 
other medical and psychiatric conditions are required 
for the diagnosis.
Key differential diagnoses to the serotonin syn-
drome are the other potentially life-threatening hyper-
thermic syndromes: neuroleptic malignant syndrome 
(NMS), malignant hyperthermia and anticholinergic 
poisoning.3 However, important points in history and 
physical examination facilitate the distinction between 
the three. NMS is a reaction to several antipsychotic 
drugs, eg, such as chlorpromazine and haloperidol.5 
NMS is due to dopamine receptor blockade and it 
usually  starts  with  muscular  rigidity  followed  by 
hyperthermia and altered consciousness. Unlike the 
serotonin syndrome, NMS is exclusively caused by 
dopaminergic drugs. Symptoms develop over days 
and resolve over days to weeks.5 In the serotonin syn-
drome, the onset and resolution of symptoms occur 
within hours. Most patients present within 6 hours of 
increasing dosage, starting a new drug, or taking an 
overdose. A history of neuroleptic usage combined 
with  the  presence  of  bradykinesia  or  “lead  pipe” 
rigidity on examination distinguishes the NMS from 
that caused by serotonin excess.5 It is important to 
note that serotonergic agents include nonprescription 
drugs, illicit drugs, and diet supplements. The time 
line of events for the patient is listed in Table 1.
Malignant  hyperthermia  (MH)  is  a  rare 
life-threatening condition that is usually triggered by 
exposure to certain drugs used for general   anesthesia; 
specifically,  the  volatile  anesthetic  agents  and  the 
neuromuscular  blocking  agent,  succinylchloine.  It 
is due to an abnormally increased release of calcium 
from  the  sarcoplasmic  reticulum.6,7  Susceptibility 
to MH is often inherited as an autosomal dominant 
disorder, for which there are at least 6 genetic loci 
of interest, most prominently the ryanodine receptor 
gene (RYR1).6 The syndrome occurs within minutes 
of exposure to the anesthetic agents, unlike   Serotonin 
syndrome,  and  presents  with  muscular  rigidity, 
a  hypermetabolic state reflecting increased oxygen 
consumption and increased carbon dioxide produc-
tion, metabolic acidosis, and hyperthermia.7 The onset 
of symptoms, history of exposure to anesthetic agents, 
Table 1. Timeline of the events for the patient.
Time pulse RR Temp Bp pulse ox
0100 AM 133 10 101.4 
(tylenol given)
140/69 Blood, urine cultures, chest   
x-ray and head CT done
0130 131  
(ativan 2 mg given)
10 100.3 135/66 Ceftriaxone and  
Vancomycin given
0235 122 8 99.9 135/65 93%
0240 112 8 
Intubated 
(CMV-TV 500, peep 5, 
Fio2 40%, R 20)
99.9 
Rapid sequence  
intubation
109/52 99% 
ABG: pH 7.19, pCo2 70.9,  
po2 177, HCo3 26.5
0330 91 20 99.7 103/51 99% 
ABG: pH 7.47, pCo2 28.2,  
po2 213, HCo3 20.3
0350 75 20 99.5 115/66 99%
0430 75 20 99.8 126/84 100%Malik et al
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family history, and physical examination positive for 
skin mottling and hyporeflexia may distinguish malig-
nant hyperthermia from serotonin   syndrome.8 On the 
other hand, anticholinergic   syndrome (ACS) is pro-
duced by the inhibition of cholinergic neurotransmis-
sion at muscarinic receptor sites. The distinguishing 
feature  of  anticholinergic  syndrome  is  dryness  of 
the  skin  compared  with  diaphoresis  in  serotonin 
syndrome.
Successful  management  of  serotonin  syndrome 
relies upon prevention, early recognition, and sup-
portive  care.  Combinations  of  serotonergic  medi-
cations should be avoided and at least 2 to 4 weeks 
should  pass  between  discontinuation  of  an  MAOI 
and initiation of another serotonergic agent.6 Acute 
management is based on 2 simple principles: discon-
tinuation of all serotonergic medications and provi-
sion of necessary supportive care. Severe forms of the 
syndrome may require aggressive measures, includ-
ing neuromuscular-blocking agents, mechanical ven-
tilation, benzodiazepines (for sedation), and external 
cooling.6 Mild cases generally resolve within 24 to 
72 hours with conservative therapy and removal of 
the causative drugs. Patients who are severely hyper-
thermic with temperatures . 41 °C (106 °F) should 
be  given  IV  sedation,  paralyzed,  and  intubated. 
Cooling blankets can be used for patients with mild 
to moderate hyperthermia.
In addition, pharmacologic therapy in the acute 
management of serotonin syndrome includes benzo-
diazepines (Lorazepam or Diazepam) and nonspecific 
serotonin receptor blockers such as cyproheptadine, 
chlorpromazine,  methysergide,  and  propranolol.6 
Benzodiazepines are used for control of agitation and 
preferred  over  physical  restraints.  The  efficacy  of 
cyproheptadine in the treatment of serotonin syndrome 
has been documented.4 Atypical antipsychotic agents 
with serotonin antagonist properties (eg, olanzapine 
10 mg SL) have been tried with some success. There 
is no role of acetaminophen in the management of 
serotonin syndrome.
conclusion
This case shows a rare incidence of serotonin syn-
drome with Escitolapram use and concomitant abuse 
of cocaine.9 It is very important that physicians are 
familiar with the signs and symptoms of Serotonin 
syndrome and should suspect it in anyone with altered 
mental status who is taking serotonin-modifying drugs. 
Because of its protean manifestations, the illness can 
easily be missed while the patient is subjected to a 
variety of unnecessary tests. In addition, the offending 
agent may be continued, causing an exacerbation of 
the syndrome with devastating consequences. This 
case emphasizes the fact that drug abusers with men-
tal  illness  on  psychotropic  pharmacological  agents 
have a very high incidence of developing serotonin 
syndrome.
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